Beacon Pharmaceuticals Limited, the leading oncology company in Bangladesh, has introduced a groundbreaking treatment for lung cancer: Tagrix, the first global generic version of osimertinib.
Learn moreThere are dedicated facilities for oral and parenteral pharmaceutical products. General Product Facility (GPF-1) and General Product Facility (GPF-2) manufacture tablets, liquid syrup, pediatric drops, powder for suspension, and liquid in hard gelatin capsules. On the other hand, we produce injectables for a diverse range of products such as biosimilar and generic products in a separate parenteral facility in a Separate Facility.
BEACON Pharmaceuticals prioritizes quality with an integrated approach towards quality control, assurance, production, and regulatory affairs. Rigorous testing and adherence to global standards have earned them approvals from health authorities worldwide.
The facility features dedicated manufacturing modules for a spectrum of Pharmaceutical products, including tablets, capsules, small volume parenterals, monoclonal antibodies, injections, dry injections, syrups and suspensions, ointments, and dry syrups. This comprehensive range caters to both export and domestic markets.